Vericel Reports 3Q18 MACI Revenue of $16.4MM, +65.7% vs. 3Q17

Vericel continued its strong performance with another quarter of record revenue, reporting MACI sales of US $16.4MM, +65.7% vs. 3Q17. MACI, available only in the U.S., uses a patient’s own cartilage cells to provide pain relief and improved function in the knee. Over 800 surgeons are now trained on the procedure since the 1Q17 launch of the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us